Interleukin-36 and Generalized Pustular Psoriasis: A Narrative Review of the Role of IL-36 in Generalized Pustular Psoriasis and an Update on Treatments

Abstract

Generalized Pustular Psoriasis (GPP) is one of the rare variants of Psoriasis vulgaris. It can be life-threatening, especially in pregnant women or in a setting of multiple co-morbidities. The pathophysiology of chronic plaque psoriasis is well known, however, that of GPP has been the subject of debate and research until recently with the identification of certain genetic mutations and inflammatory mediators. Traditionally, the same treatments for Chronic plaque psoriasis have been used to treat GPP, with variable success, which led to investigations into the pathobiology of GPP. The recent identification of the role of interleukin-36 and its receptor has led to an understanding of the pathophysiology of the disease. This knowledge has allowed the development of novel biologic treatments that target interleukin-36 inflammatory pathways and could revolutionize how dermatologists manage GPP. In this review, we discuss the role of interleukin-36 in GPP and its treatment.